Insulin Versus Oral Hypoglycemic Agents in Gestational Diabetes Mellitus

A prevalent problem among pregnant women, gestational diabetes mellitus (GDM) typicallymanifests in the second and third trimesters. However, the reported frequency of GDM alsovaries globally due to variations in GDM diagnosis criteria. GDM raises the risk ofharmful prenatal complications for both the mother and the fetus because of poorlymanaged blood glucose. Nonetheless, the application of more stringent criteria for thediagnosis of GDM (IADPSG criteria) is advised due to the recent advancements in ourunderstanding of the condition, which will help with blood glucose control duringpregnancy. Women are recommended to use diet and exercise to control their blood glucoselevels after receiving a diagnosis of GDM. However, hypoglycemic medications like asinsulin, metformin, glyburide, and in certain trials, acarbose, should be used for peoplewho are unable to regulate their blood glucose.When lifestyle changes are not successful, insulin has been the recommended treatment forGDM since it regulates blood glucose levels without passing through the placenta. Theneeds of each patient can be met by combining and matching formulations of short‐ andlong‐acting insulin. As treatments for GDM, oral hypoglycemic drugs such glyburide andmetformin are becoming more and more well‐liked. Metformin decreases the liver'sproduction of glucose and increases insulin sensitivity, both of which result in lowerblood glucose levels.6Gluburide encourages the pancreas to secrete more insulin. Despitebeing convenient and well‐tolerated, there has been much debate and research over thesafety and efficacy of oral administration during pregnancy.